featured
The Feasibility and Benefits of Applying PERCIST for Response Monitoring in Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diagnostics (Basel, Switzerland)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST
Diagnostics (Basel) 2021 Apr 19;[EPub Ahead of Print], M Vogsen, JL Bülow, L Ljungstrøm, HR Oltmann, TA Alamdari, M Naghavi-Behzad, PE Braad, O Gerke, MG HildebrandtFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.